Skip to content

Anti-aging & longevity

Adalank

N-Acetyl Selank Amidate · NA-Selank-Amidate · Selank amidate

PreclinicalReviewed 18 Aug 2026

Adalank is N-acetyl Selank amidate: Selank with an acetyl group at one end and an amide at the other, capped against the enzymes that would otherwise break it down.

Selank itself is a synthetic analogue of tuftsin, developed in Russia as an anxiolytic that does not sedate, and registered there. It has a genuine clinical record, of the kind this site describes carefully rather than dismisses.

The amidated version does not share that record. It is presumed to be more potent and longer-lasting on the same reasoning as its Semax counterpart, and no human trial has tested it. Anyone choosing it over Selank is choosing a potency claim over a clinical history.

How it works

Selank is derived from tuftsin, a naturally occurring immunomodulatory peptide fragment, and is understood to affect GABA and serotonin signalling as well as BDNF expression. Its anxiolytic effect is described as occurring without sedation, which is the property that distinguishes it from benzodiazepines.

The terminal modifications change duration rather than target. Capping the ends slows enzymatic breakdown; it does not alter what the molecule binds.

Whether a longer-acting anxiolytic peptide behaves like a stronger one or simply a more persistent one is not established, and the distinction matters for something affecting GABA signalling.

Regulatory status — United States

Not approved anywhere. Selank is registered in Russia as an anxiolytic; this modified version is not, and has never been studied in a human trial. Sold only as a research chemical.

Last reviewed 18 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Anxiety and stress

Published review

What Selank is registered for in Russia, and why this is bought.

EvidenceSelank has Russian clinical registration. The amidated form has no human trial of its own.

Identity and clearance

Molecule

Class
N-acetylated, C-amidated analogue of Selank
Length
7 amino acids

Same backbone as Selank with both termini capped against enzymatic degradation.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 10 mg vialSourceStart this protocol
Commonly described community protocol250 mcg – 750 mcgOnce or twice dailyNasalLower than Selank figures on the assumption of greater potency. That assumption rests on animal work, and no human study establishes the equivalence.12.5–37.5 uCommunity practiceStart this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Calculator

Work out what to draw

Pre-filled with a 20 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Dose unit
Your syringe
01020304050607080901005 units0.05 mL

Draw to 5 units on a 1 mL U-100 syringe. That is 0.05 mL, containing 500 mcg of Adalank.

Concentration10mg / mL
Volume drawn0.05mL
Doses per vial40doses
Per unit100mcg / unit

Check5 units falls between the printed lines on a 1 mL U-100 syringe. Mixing with 1.6 mL of water instead would put this dose at 4 units.

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

  • Nasal irritationCommunity practice

    Commonly reported

  • Drowsiness or flatness of moodCommunity practice

    Occasionally reported

    Selank's stated advantage is anxiolysis without sedation. A longer-acting version being described as sedating is worth noticing.

  • Everything elseCommunity practice

    Unknown

    The modified molecule has never been studied in a person.

When to stop

  • Worsening mood, flatness, or any thought of harming yourself. Seek help.
  • Sedation that interferes with driving or work.
  • Nasal pain, bleeding or discharge.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Interactions and situations that need care

  • Any psychiatric condition, or antidepressant or anxiolytic therapyAvoid

    A compound affecting GABA and serotonin signalling, with no human data in this form, added to a condition already being treated with drugs acting on the same systems, is an interaction nobody can predict.

  • Pregnancy and breastfeedingAvoid

    No reproductive or developmental safety data.

  • Treating anxiety without assessmentUse caution

    Anxiety that warrants treatment warrants a diagnosis, and there are treatments with decades of trial evidence behind them. Substituting an unstudied peptide is choosing the option with the least support.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

  • No human trial of the amidated form exists. The clinical record belongs to Selank.
  • The modification changes duration, not target.
  • Selank's selling point is anxiolysis without sedation, and the longer-acting version is more often described as sedating.
  • If the Russian clinical record is what interests you, it belongs to Selank rather than to this.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Nasal solutions are handled more than injectables and are correspondingly easier to contaminate.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

With other peptides

  • Selankcaution

    This is a modified Selank. Running both is taking the same compound twice, once in a form with Russian clinical registration and once in a form with none.

Check this against a whole stack

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

  • White cake, clear solution

    Standard for a short peptide.

  • Collapsed cake or cloudy solution

    Heat damage or degradation. Do not use it.

Questions

How is it different from Selank?
Both ends are chemically capped so it survives longer. That is the only difference in what the molecule is. The difference in what is known about it is much larger.
Is Selank a benzodiazepine?
No. It affects GABA signalling but is not a benzodiazepine, and its stated advantage is reducing anxiety without the sedation and dependence that class carries. That claim is from the Russian literature.

References

  1. Russian clinical literature on regulatory peptides and nootropics: scope and limits

    Russian pharmacology and psychiatry literature, 2015 · Body of clinical work, largely unregistered and not blinded to contemporary standards

    Humans

    Reports anxiolytic, nootropic and neuroprotective effects supporting registration of several of these compounds in Russia. Methodology, reporting standards and the absence of independent replication limit how much weight the findings carry elsewhere.

  2. Commonly reported community protocols

    Bioalmanac editorial summary of public community sources, 2026 · Not a study

    Records dose and route patterns described in public discussion. Carries no evidential weight about safety or effect.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 18 Aug 2026